Sunday, June 12, 2022 9:30:19 AM
Topic: NICE Sticks it to Nissen!
On June 10, 2022, The National Institute for Health and Care Excellence (NICE, England) published the Final Draft Guidance which recommends icosapent ethyl for reducing the risk of cardiovascular events such as heart attacks and strokes in adults who have raised levels of triglycerides. https://www.nice.org.uk/search?q=icosapent
This comes after a long process of gaining Marketing Authorization Approval in the EU & UK, (921 days), and 880 days after the failure of the STRENGTH Trial, (1/14/2020). For the past two and a half years the PI of that RTC (Dr. Steve Nissen) has been on a “sour grapes” campaign to discredit the results of the REDUCE-IT trial. In that 2.5-year period the FDA, the EMA and now NICE have correctly determined that the clinical effect of the mineral oil placebo had little to do with the final outcomes.
Recent AMRN News
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM
ECGI Holdings Targets $9.7 Billion Equestrian Apparel Market with Allon Brand Launch • ECGI • Jun 25, 2024 8:36 AM
Avant Technologies Addresses Progress on AI Supercomputer-Driven Data Centers • AVAI • Jun 25, 2024 8:00 AM
Green Leaf Innovations, Inc. Expands International Presence with New Partnership in Dubai • GRLF • Jun 24, 2024 8:30 AM
Bemax Inc. Positions to Capitalize on Industry Growth with New Improved Quality of Mother's Touch® Disposable Diapers • BMXC • Jun 24, 2024 8:00 AM
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
